Fig. 7From: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIFlow cytometry gating strategy for CD4+ and CD8+ cells. Lymphocytes were first identified by R1 gate in forward scatter (FSC) and side scatter (SSC) graph. CD4+ and CD8+ T cells were then measured by means of anti CD4 and anti CD8 antibodies, labeled by FITC and PE respectively; as illustrated in the histogram graphs separately. A and B represent the changes in CD4+ and CD8+ lymphocyte counts between 5 and 10Â days after secretome administration in a 35-year-old male patient, respectivelyBack to article page